0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0
12
24
36
48
60
72
84
96
108
120
Ipilimumab
CENSORED
3-year OS rate, 21% Ipilimumab Pool analysis
Proportion Alive
Months
Melanoma:
Long Term Overall Survival
5-year OS rate, 35% Nivolumab Phase I
3-year OS rate, 40% Pembrolizumab Phase I
©️Arance
Schadendorf et al. J Clin Oncol 2015
